Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy

Henan Cancer Hospital · 2026
ClinicalTrials.gov · Datasets · License: Public Domain · 2026
Open Source ↗
bcl
mantle cell lymphoma (mcl), relapsed mantle cell lymphoma, refractory mantle cell lymphoma, btk inhibitor, bcl-2 inhibitor, non-covalent btk inhibitor, lisaftoclax, pirtobrutinib, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 850167
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.